June 9, 2020
Royalty Pharma buys partial royalty interest on Prevymis from AiCuris Anti-infective Cures GmbH
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.